Cancer Genetics Sharply Higher After Interpace Buys Biopharma Unit

Cancer Genetics CGIX shares are trading sharply higher after Interpace Diagnostics IDXG said it purchased the Biopharma Services unit of the Cancer Genetics.

Interpace Diagnostics shares are also trading higher after Ampersand Capital Partners agreed to invest $27 million in the company in two tranches of newly issued convertible preferred stock.

Cancer Genetics shares are up 53% at 27 cents in Tuesday’s pre-market session. The stock has a 52-week high of $1.30 and a 52-week low of 15 cents per share.

Interpace Diagnostics shares are up 3.8% at 72 cents in Tuesday’s pre-market session. The stock has a 52-week high of $1.78 and a 52-week low of 67 cents per share.

Related Links:

JPMorgan Q2 Earnings Beat Estimates

Johnson & Johnson Trades Higher On Q2 Earnings Beat